Therapeutic Solutions International Inc (TSOI)

[centsability4me]

TSOI DD/NEWS/SS

TSOI Products

5 Biologics, 6 Nutraceuticals, 1 Pharmaceutical = 12

6 TSOI nutraceutical products released from granted patent
Projuvenol, NanoStilbene, DermalStilbene, IsoStilbene, NeuroStilbene, Alpha Lipoic Acid
https://patents.google.com/patent/US9682047B2/en

4 TSOI nutraceutical products for sale online
Projuvenol, Nanostilbene, DermalStilbene, NeuroStilbene
http://www.youcanordernow.com/

5 Biologics, 1 Pharmaceutical licensed to Pan Am Cancer Treatment Center in Mexico
StemVacs, Cancer Metabolic DeTox, innaMune, LymphoBoost, MemoryMune, BRS-001
http://ih.advfn.com/p.php?pid=nmona&article=77606645
http://ih.advfn.com/p.php?pid=nmona&article=77309980
http://ih.advfn.com/p.php?pid=nmona&article=77635806

Pan Am Cancer Treatment Center Introductory Tour Video
https://www.youtube.com/watch?v=rWgJLRCICa8&feature=youtu.be
News

StemVacs Immunotherapy Platform for TSOI RTT Cancer Clinic
http://stemvacs.com/

StemVacs Patents - Products - PRs

Patent Title: Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants Cancer Metabolic DeTox
http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-targeting-tumor-microenvironment-through-nutraceutical-otc-pink-tsoi-2215015.htm
Patent Title: Methods of Re-Activating Dormant Memory Cells with Anticancer Activity MemoryMune
http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-methods-re-activating-dormant-memory-cells-with-otc-pink-tsoi-2220094.htm
Patent Title: Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization StemVacs
http://www.marketwired.com/press-release/therapeutic-solutions-international-announces-filing-new-immunotherapy-patent-exclusive-otc-pink-tsoi-2208787.htm
Patent Title:Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof LymphoBoost
http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-augmentation-anti-tumor-immunity-mifepristone-otc-pink-tsoi-2217703.htm
Patent Title: Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients innaMune
http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-blood-derived-innate-immune-system-stimulator-otc-pink-tsoi-2216672.htm
Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of "Universal Cancer Antigen" into StemVacs Dendritic Cell Platform BRS-001
http://ih.advfn.com/p.php?pid=nmona&article=77635806

TSOI PR History 5/1- 9/4/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143641732

NEWS 9/25/18
https://ih.advfn.com/p.php?pid=nmona&article=78326088

Therapeutic Solutions International Files Patent on Clinical Data Demonstrating Reduction of Inflammatory Cytokines Using NanoStilbeneTM

Oceanside, CA -- September 25, 2018 -- InvestosHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today filing of a patent covering novel clinical data using its NanoStilbeneTM formulation to reduce inflammatory cytokine production in cancer patients.

It is known that these hormone-like substances, called cytokines, often reduce the efficacy of immunotherapy. The Company believes that by reducing inflammatory cytokines, administration of NanoStilbene may be used to increase the efficacy of multibillion dollar a year cancer immunotherapy drugs such as Herceptin.

"The data in the patent filed today is highly applicable to the major obstacle of cancer immunotherapy, which is, the chronic inflammatory state in advanced cancer patients," said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "As a physician who has personally seen the promise of Immunotherapy, it is my personal mission to ensure that we increase efficacy and decrease the toxicity of immunotherapy using practical and simple to implement methods such as NanoStilbene."

Immunotherapy is a new type of cancer therapy that uses the immune system to selectively seek and destroy tumor cells. In contrast to chemotherapy or radiation therapy, immunotherapy teaches the immune system to not only kill cancer but to "learn" from its encounters and effectively fight recurrence and metastasis.

"The studies, which were conducted in advanced cancer patients, demonstrated that daily administration of 10ml of NanoStilbene resulted in the reduction of TNF-alpha, CRP, and IL-6, all proteins associated with chronic inflammation. One of the most advanced immunotherapies is the use of CAR-T cells, whose dose-limiting toxicity is associated with the production of inflammatory cytokines. The data filed in the patent suggest the possibility of using NanoStilbene to reduce side effects of this type of immunotherapy" said Timothy Dixon, President, and CEO of TSOI. "These data, which will be formally published in the peer-reviewed literature, we believe, strongly support the implementation of NanoStilbene in patients with advanced cancer."

NEWS 9/19/2018
https://ih.advfn.com/p.php?pid=nmona&article=78289796

Therapeutic Solutions International Collaborates with Internationally Renowned Neurologist and NFL Charger Hall of Famer to Develop New Intellectual Property for Treatment of Chronic Traumatic Encephalopathy
Company Files Patent and Generates Proof of Concept Data using NeuroStilbene for Prevention of Football Associated Brain Damage

OCEANSIDE, CA -- September 19, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today new data demonstrating the ability of its NeuroStilbene intranasal formulation of pterostilbene to successfully prevent the development of brain injury in an animal model of Chronic Traumatic Encephalopathy.

Through a collaboration with its Scientific Advisory Board Member Dr. Santosh Kesari, and NFL Chargers Hall of Famer Wes Chandler, the Company has filed a patent covering these new findings and means of utilizing pterostilbene based formulations for prevention and treatment of Chronic Traumatic Encephalopathy.

"The current data provided in the patent strongly supports the possibility that receiving NeuroStilbene before sports-related brain injuries will prevent the development of Chronic Traumatic Encephalopathy," said Wes Chandler, Chairman of the TSOI CTE Advisory Board. "As someone who personally suffers from Chronic Traumatic Encephalopathy, including depression, memory loss, hand tremors, and a loss even of my penmanship, I can speak first hand on the urgent need to provide players with medical solutions to prevent the development of CTE. It is our intention to add additional athletes who suffer from similar types of ailments from all sports and not just football to the CTE Advisory Board. This is not about abolishing professional sports entities, but an attempt to collaborate for prevention and treatment of this terrible condition."

Chronic Traumatic Encephalopathy is a major problem in football, other contact sports, and military veterans. This condition has been seen in people as young as 17, but symptoms do not generally begin appearing until years after the onset of head impacts. Common symptoms of Chronic Traumatic Encephalopathy in the early stages of the condition include impulse control problems, aggression, depression, and paranoia. As the disease progresses, some patients may experience problems with thinking and memory, including memory loss, confusion, impaired judgment, and eventually progresses to dementia.

"NeuroStilbene is a nanotechnology-based formulation of pterostilbene which is produced from naturally occurring ingredients and is currently available for purchase as a nutraceutical. Although our recent data demonstrates a reduction in tau and suppression of brain cell damage with NeuroStilbene, clinical trials are needed before specific medical claims can be made," said Dr. James Veltmeyer, Chief Medical Officer of the Company and Vice Chairman of the CTE Advisory Board. "That being said, there are numerous peer reviewed scientific publications showing pterostilbene protects against brain damage in a variety of settings. For example, some studies show pterostilbene suppresses inflammation associated memory decline [1,2], other studies show pterostilbene suppresses hemorrhagic brain injury and neuronal cell death[3,4] and yet other ones show protection of the brain against damage associated with lack of oxygen and aging[5,6,7]. Given all this supporting data, it is a logical extension to believe that NeuroStilbene, which is a more potent formulation of pterostilbene, would possess activity against Chronic Traumatic Encephalopathy."

Previous clinical studies by the Company have demonstrated that NanoStilbene possesses superior distribution and half-life of pterostilbene when administered to healthy volunteers.

"The filing of today's patent represents a successful collaboration between medical, basic research, and sports experts," said Timothy Dixon, President, and CEO of TSOI. "It is our honor to work with experts such as Dr. Kesari who understand not only the basic science of how the healthy and diseased brain works but also possess the medical insight to translate findings into patients."

Share Structure
https://www.otcmarkets.com/stock/TSOI/security
AS - 1.5 B common , 5 M preferred - https://www.nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=LvtIoYTPV6wB1RIovm008A%253d%253d&nt7=0
IO - 931,175,844
Restricted - 816,540,972
Unrestricted - 114,634,872
Held at DTC - 91,991,872
Float - 70,343,547
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=therapeutic+solutions+international&match=contains&action=getcompany

Transfer Agent
New Horizon Transfer Inc.
215-515 West Pender Street
Vancouver, BC V6B 6H5
CAN(604) 876-5526
www.newhorizontransfer.com


Contact

Investor Relations
[e-mail]
Corporate Website
http://therapeuticsolutionsint.com/
Additional info
http://projuvenol.com/
E Commerce Site
http://www.youcanordernow.com/
TSOI on Facebook
https://www.facebook.com/tsoihome/
TSOI on Twitter
https://twitter.com/tsoisupplement